Why Pharmaceutical Resilience Is Critical in Drug Manufacturing
Pharmaceutical resilience is essential to strengthening the U.S. drug supply chain against shortages, global dependencies, and emerging risks.
READ MORE
IN THE NEWS
Ritedose news
and updates.
Learn more about Ritedose and the community.
Press releases, news stories, partnerships, community events, and more.
Media Inquiries
Schedule your interview and learn more about the Ritedose Company.
Ritedose Reaches “1,000 Hours of Purpose”
Employee-led initiative deepens Ritedose’s commitment to Midlands nonprofits and the communities they serve.
READ MORE
Ritedose, University of South Carolina Welcome Top European Business Students for Immersive Learning about Advanced Manufacturing
– Collaboration showcases the Ritedose Center of Excellence as a global hub for advanced manufacturing education. – The Center of Excellence serves as a cornerstone of Ritedose’s broader commitment to workforce development and industry leadership.
READ MORE
What Does it Mean to be a Manufacturer of Choice?
Ritedose explains how quality, reliability, and Blow-Fill-Seal (BFS) expertise define what it means to be a true manufacturer of choice in pharmaceutical manufacturing.
READ MORE
Ritedose Announces Manufacturing for Tenpoint Therapeutics’ Presbyopia Eye Drop
Partnership Signals Commercial Readiness and Manufacturing Strength for Groundbreaking Ophthalmic Treatment.
READ MORE
Meeting Patient Needs Through Flexible Pharmaceutical Manufacturing
Pharmaceutical manufacturing at scale requires flexibility, cGMP compliance and advanced technology to ensure safe, reliable medications for patients.
READ MORE
Blow-Fill-Seal: How Ritedose Is Setting the Standard in Pharmaceutical Manufacturing
Blow-Fill-Seal manufacturing is transforming sterile pharmaceutical production, and Ritedose is setting the standard through innovation, quality systems and scalable CDMO expertise.
READ MORE
How Ritedose Addresses Drug Shortages
Ritedose helps address drug shortages by using advanced sterile manufacturing and strategic partnerships to keep essential treatments available.
READ MORE
Ritedose Honored With SCbio’s 2026 Life Sciences Pinnacle Award for Organizational Contribution
South Carolina’s largest sterile CDMO recognized for visionary leadership, innovation, and community impact at SCbio’s annual Life + Science Conference.
READ MORE
South Carolina Life Sciences Momentum: Ritedose Helps Fuel a Fast-Growing Innovation Hub
Ritedose is helping shape a new era of innovation in South Carolina, where life sciences companies are scaling faster than ever before.
READ MORE
Introducing Ritedose— the Largest CDMO Specializing in Blow-Fill-Seal Technology in the US
This overview explores Ritedose, the largest U.S. pharmaceutical CDMO, and how its aseptic Blow-Fill-Seal technology supports large-scale branded and generic drug manufacturing.
READ MORE
How Ritedose Supports a Stable and Reliable Medication Supply
Learn how Ritedose safeguards patients’ access to critical medications with responsive, high-quality pharmaceutical manufacturing.
READ MORE
Ritedose 2025 Year-In-Review
Ritedose’s 2025 Year-In-Review highlights a year of growth, innovation, and purpose-driven impact, advancing patient access through expanded generics, operational excellence, and community investment.
READ MORE
A Season of Gratitude and Purpose: A Thanksgiving Message from Jody Chastain, CEO of Ritedose
Ritedose has been built on the generosity, mentorship, and support of countless individuals and organizations across South Carolina. And with that good fortune comes a responsibility to give back to our patients, our people, and our community.
READ MORE
Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution
The Ritedose Corporation (Ritedose) announced that the U.S. Food and Drug Administration (FDA) approved its manufacturing and distribution of Tobramycin Inhalation Solution to treat patients six years and older with infections of Pseudomonas aeruginosa, a common bacterial infection among cystic…
READ MORE
Leading CDMO Enhances cGMP Lab Infrastructure to Strengthen Position
Ritedose is investing $17M to expand its cGMP labs, adding a 10,000 sq. ft. analytical chemistry facility and a 6,000 sq. ft. microbiology expansion to boost drug development and CDMO capabilities.
READ MORE
How Blow-Fill-Seal Technology Ensures Sterile Medication Delivery
Discover how Ritedose leads the industry in delivering safe, scalable, and contamination-free drug products through advanced BFS innovation.
READ MORE
Ritedose Unveils State-of-the-Art Distribution and Logistics Facility at Ritedose Performance Park
COLUMBIA, SC, June 18, 2025 – The Ritedose Corporation, a leading pharmaceutical manufacturer specializing in Blow-Fill-Seal (BFS) technology, today unveiled its new distribution and logistics facility at Performance Park during a ribbon-cutting ceremony. The grand opening event included Ritedose CEO…
READ MORE
Ritedose Pharmaceuticals Receives FDA Approval for Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*—Addressing Nationwide Shortage of the Essential Drug
COLUMBIA, SC May 20, 2025 —Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), the largest sterile contract development manufacturing organization (CDMO) in the US specializing in aseptic unit-dose medication production using Blow-Fill-Seal (BFS) technology, received US Food and Drug…
READ MORE
Ritedose Pharmaceuticals Receives FDA Approval for Generic Formoterol Fumarate Inhalation Treatment for Respiratory Illness
COLUMBIA, SC May 1, 2025 — Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), was granted approval by the US Food and Drug Administration (FDA) to manufacture and market generic formoterol fumarate inhalation solution (20 mcg/2 mL), a treatment…
READ MORE
FEATURED NEWS
RECEIVE THE LATEST NEWS
Get a healthy dose of all things Ritedose. Subscribe now for breaking news alerts, updates, previews, and more.